Janus kinase inhibitors: another potential for uveitis treatment?
作者信息
Emami Seema, Kaisari Eirini, Janetos Timothy M
机构信息
Department of Ophthalmology, Northwestern University, Chicago, IL, USA.
出版信息
Ann Eye Sci. 2025 Jun 30;10. doi: 10.21037/aes-25-2.
Abstract
摘要
相似文献
1
Janus kinase inhibitors: another potential for uveitis treatment?Janus激酶抑制剂：葡萄膜炎治疗的另一种潜力？
Ann Eye Sci. 2025 Jun 30;10. doi: 10.21037/aes-25-2.
2
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.Janus 激酶抑制剂治疗对幼年特发性关节炎成年患者前葡萄膜炎及相关黄斑水肿的疗效。
Ocul Immunol Inflamm. 2019;27(8):1232-1234. doi: 10.1080/09273948.2019.1605453. Epub 2019 Jul 3.
3
Janus Kinase Inhibitors: Next-Generation Treatment for Uveitis.Janus 激酶抑制剂：葡萄膜炎的下一代治疗方法。
Klin Monbl Augenheilkd. 2022 May;239(5):695-701. doi: 10.1055/a-1741-8104. Epub 2022 Apr 14.
4
A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis.乙酰唑胺治疗葡萄膜炎患者黄斑囊样水肿的随机、双盲、交叉试验。
Ophthalmology. 1996 Jul;103(7):1054-62; discussion 1062-3. doi: 10.1016/s0161-6420(96)30567-8.
5
Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema.葡萄膜炎相关黄斑囊样水肿中的房水和血浆血管内皮生长因子
Am J Ophthalmol. 2001 Nov;132(5):794-6. doi: 10.1016/s0002-9394(01)01103-5.
6
Inflammatory cystoid macular edema.炎性囊样黄斑水肿
Curr Opin Ophthalmol. 2007 Nov;18(6):487-92. doi: 10.1097/ICU.0b013e3282f03d2e.
7
Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.用于治疗与非感染性葡萄膜炎相关的难治性黄斑囊样水肿的抗TNF-α制剂
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):633-40. doi: 10.1007/s00417-013-2552-8. Epub 2013 Dec 24.
8
Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis.生物制剂或靶向合成药物治疗中轴型脊柱关节炎患者葡萄膜炎的发生率：系统评价和网络荟萃分析。
Arthritis Rheumatol. 2024 May;76(5):704-714. doi: 10.1002/art.42788. Epub 2024 Apr 13.
9
Etanercept monotherapy induces complete resolution of cystoid macular edema in a patient with intermediate uveitis.
Retin Cases Brief Rep. 2007 Fall;1(4):261-3. doi: 10.1097/01.iae.0000242843.02952.46.
10
Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients.与使用拉坦前列素相关的黄斑囊样水肿和前葡萄膜炎。对94例患者进行回顾性研究的经验及发病率
Ophthalmology. 1998 Feb;105(2):263-8. doi: 10.1016/s0161-6420(98)92977-3.
本文引用的文献
1
Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries.Janus激酶抑制剂在非感染性炎症性眼病中的疗效与安全性：一项来自国际AIDA网络注册库的前瞻性队列研究。
Front Med (Lausanne). 2024 Aug 23;11:1439338. doi: 10.3389/fmed.2024.1439338. eCollection 2024.
2
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.法特替尼治疗活动性非感染性葡萄膜炎的疗效：一项 HUMBOLDT 随机临床试验
JAMA Ophthalmol. 2024 Sep 1;142(9):789-797. doi: 10.1001/jamaophthalmol.2024.2439.
3
Tofacitinib for Refractory Uveitis and Scleritis in Children: A Case Series.托法替尼治疗儿童难治性葡萄膜炎和巩膜炎：病例系列研究。
Ocul Immunol Inflamm. 2024 Nov;32(9):2092-2095. doi: 10.1080/09273948.2024.2323671. Epub 2024 Mar 5.
4
SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.SOCS-JAK-STAT 抑制剂和 SOCS 模拟物作为治疗自身免疫性葡萄膜炎、银屑病、狼疮和自身免疫性脑炎的选择。
Front Immunol. 2023 Oct 26;14:1271102. doi: 10.3389/fimmu.2023.1271102. eCollection 2023.
5
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.在炎症性疾病男性患者中，Filgotinib 对精液参数和性激素的影响：来自 2 期、随机、双盲、安慰剂对照的 MANTA 和 MANTA-RAy 研究结果。
Ann Rheum Dis. 2023 Aug;82(8):1049-1058. doi: 10.1136/ard-2023-224017. Epub 2023 May 3.
6
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.Janus 激酶抑制剂在炎症性肠病中的安全性。
Drugs. 2023 Mar;83(4):299-314. doi: 10.1007/s40265-023-01840-5. Epub 2023 Mar 13.
7
JAK inhibitors and autoimmune rheumatic diseases.JAK抑制剂与自身免疫性风湿疾病
Autoimmun Rev. 2023 Apr;22(4):103276. doi: 10.1016/j.autrev.2023.103276. Epub 2023 Jan 14.
8
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).巴瑞替尼治疗幼年特发性关节炎相关葡萄膜炎或慢性前房抗核抗体阳性葡萄膜炎的有效性和安全性：一项开放标签、阿达木单抗活性对照的 3 期临床试验研究方案（JUVE-BRIGHT）。
Trials. 2021 Oct 9;22(1):689. doi: 10.1186/s13063-021-05651-5.
9
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.JAK 抑制剂治疗类风湿关节炎：聚焦当下，展望未来。
Biomolecules. 2020 Jul 5;10(7):1002. doi: 10.3390/biom10071002.
10
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.JAK 抑制剂治疗难治性幼年特发性关节炎相关葡萄膜炎。
Clin Rheumatol. 2020 Mar;39(3):847-851. doi: 10.1007/s10067-019-04875-w. Epub 2020 Jan 2.
Zotero 插件